Trial Profile
A Phase II/III Randomized, Open-Label Study of Toca 511, A Retroviral Replicating Vector, Combined With Toca FC With Temozolomide and Radiation Followed by Adjuvant Temozolomide and Toca FC Compared to Temozolomide and Radiation Followed by Adjuvant Temozolomide in Patients With Newly Diagnosed Glioblastoma
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase II/III
Latest Information Update: 04 Nov 2021
Price :
$35
*
At a glance
- Drugs Vocimagene amiretrorepvec-flucytosine gene therapy (Primary) ; Vocimagene amiretrorepvec-flucytosine gene therapy (Primary) ; Temozolomide
- Indications Anaplastic astrocytoma; Glioblastoma; Oligodendroglioma
- Focus Therapeutic Use
- 20 Mar 2020 Status changed from not yet recruiting to withdrawn prior to enrolment.
- 08 Nov 2019 According to an Tocagen media release, this study will be presented at the 24th Annual Meeting of the Society for Neuro-Oncology (SNO).
- 24 Sep 2019 Status changed from planning to not yet recruiting.